Abstract
This article has been withdrawn because Professor Shauna Culshaw was erroneously included as an author.
References
Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008; 112:1557-1569 https://doi.org/10.1182/blood-2008-05-078154
Medicines, Diagnostics and Personalised Medicine Policy Team, National Medical Directorate, NHS England. Commissioning framework for biological medicines (including biosimilar medicines). 2017. https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf (accessed March 2022)
Royal College of Physicians. National clinical audit of biological therapies – Annual report 2016. https://www.rcplondon.ac.uk/projects/outputs/national-clinical-audit-biological-therapies-annual-report-2016 (accessed March 2022)
NICE. Platelets – abnormal counts and cancer. 2021. https://cks.nice.org.uk/topics/platelets-abnormal-counts-cancer/ (accessed March 2022)
Scottish Dental Clinical Effectiveness Programme (SDCEP). Management of dental patients taking anticoagulants or antiplatelet drugs. 2015. http://www.sdcep.org.uk/published-guidance/anticoagulants-and-antiplatelets/ (accessed January 2022)
Radfar L, Ahmadabadi RE, Masood F, Scofield RH. Biological therapy and dentistry: a review paper. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120:594-601 https://doi.org/10.1016/j.oooo.2015.07.032
Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016; 2:151-153 https://doi.org/10.1016/j.ijwd.2016.09.003
Zhao L, Ren TH, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin. 2012; 33:1339-1347 https://doi.org/10.1038/aps.2012.51
Bingham CO, Moni M. Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions. Curr Opin Rheumatol. 2013; 25:345-353 https://doi.org/10.1097/BOR.0b013e32835fb8ec
Savioli C, Ribeiro AC, Fabri GM Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. J Clin Rheumatol. 2012; 18:180-184 https://doi.org/10.1097/RHU.0b013e31825828be
NICE. Final appraisal determination adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. 2008. http://www.nice.org.uk/guidance/gid-tag393/documents/rheumatoid-arthritis-adalimumab-etanercept-and-infliximab-sequential-use-final-appraisal-determination3 (accessed January 2022)
NICE. Infliximab. 2022. https://bnf.nice.org.uk/drug/infliximab.html (accessed March 2022)
Scottish Dental Clinical Effectiveness Programme (SDCEP). Oral health management of patients at risk of medication-related osteonecrosis of the jaw. 2017. http://www.sdcep.org.uk/published-guidance/medication-related-osteonecrosis-of-the-jaw/ (accessed January 2022)
Nifosì AF, Zuccarello M, Nifosì L Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology. J Korean Assoc Oral Maxillofac Surg. 2019; 45:3-8 https://doi.org/10.5125/jkaoms.2019.45.1.3
Cassoni A, Romeo U, Terenzi V Adalimumab: another medication related to osteonecrosis of the jaws?. Case Rep Dent. 2016; 2016 https://doi.org/10.1155/2016/2856926
Biologics and Dentistry: Implications for Dental Treatment and Patient Management [WITHDRAWN]
From Volume 49, Issue 4, April 2022 | Pages 348-350
Article
Register now to continue reading
Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:
What's included
- Up to 2 free articles per month
- New content available